Abstract
Comparative molecular field analysis (CoMFA) studies were conducted on a series of 100 isoniazid derivatives as anti-tuberculosis agents using two receptor-independent structural data set alignment strategies: (1) rigid-body fit, and (2) pharmacophore-based. Significant cross-validated correlation coefficients were obtained (CoMFA(1), q2 =0,75 and CoMFA(2), q2 = 0.74), indicating the potential of the models for untested compounds. The models were then used to predict the inhibitory potency of 20 test set compounds that were not included in the training set, and the predicted values were in good agreement with the experimental results.
Keywords: Tuberculosis, Hydrazides, Drug design, QSAR, CoMFA, Galahad
Letters in Drug Design & Discovery
Title: Three-Dimensional Quantitative Structure-Activity Relationships for a Large Series of Potent Antitubercular Agents
Volume: 5 Issue: 6
Author(s): Carolina Horta Andrade, Livia de Barros Salum, Kerly Fernanda Mesquita Pasqualoto, Elizabeth Igne Ferreira and Adriano Defini Andricopulo
Affiliation:
Keywords: Tuberculosis, Hydrazides, Drug design, QSAR, CoMFA, Galahad
Abstract: Comparative molecular field analysis (CoMFA) studies were conducted on a series of 100 isoniazid derivatives as anti-tuberculosis agents using two receptor-independent structural data set alignment strategies: (1) rigid-body fit, and (2) pharmacophore-based. Significant cross-validated correlation coefficients were obtained (CoMFA(1), q2 =0,75 and CoMFA(2), q2 = 0.74), indicating the potential of the models for untested compounds. The models were then used to predict the inhibitory potency of 20 test set compounds that were not included in the training set, and the predicted values were in good agreement with the experimental results.
Export Options
About this article
Cite this article as:
Andrade Horta Carolina, Salum de Barros Livia, Mesquita Pasqualoto Fernanda Kerly, Ferreira Igne Elizabeth and Andricopulo Defini Adriano, Three-Dimensional Quantitative Structure-Activity Relationships for a Large Series of Potent Antitubercular Agents, Letters in Drug Design & Discovery 2008; 5(6) . https://dx.doi.org/10.2174/157018008785777289
DOI https://dx.doi.org/10.2174/157018008785777289 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Editorial [Hot Topic: N-Acetyltransferases: Lessons Learned from Eighty Years of Research (Guest Editor: Jose A.G. Agundez) ]
Current Drug Metabolism Drug Approval Process – In United States of America, European Union and India: A Review
Applied Clinical Research, Clinical Trials and Regulatory Affairs Quinolone-Based Drugs Against Toxoplasma gondii and Plasmodium spp
Current Drug Targets - Infectious Disorders Developing Country Applications of Molecular Farming: Case Studies in South Africa and Argentina
Current Pharmaceutical Design Evaluation of Brazilian Biotechnology Patent Activity from 1975 to 2010
Recent Patents on DNA & Gene Sequences Understanding the Molecular Mechanisms of Rifaximin in the Treatment of Gastrointestinal Disorders – A Focus on the Modulation of Host Tissue Function
Mini-Reviews in Medicinal Chemistry Bacterial Cell Division Regulation by Ser/Thr Kinases: A Structural Perspective
Current Protein & Peptide Science Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine The Role of Electrospinning in the Emerging Field of Nanomedicine
Current Pharmaceutical Design Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Biomarkers of Impaired Innate and Adaptive Immunity in Health and Disease)
Current Immunology Reviews (Discontinued) Designing Type II Topoisomerase Inhibitors: A Molecular Modeling Approach
Current Topics in Medicinal Chemistry Biomarkers of Asthma: Recent Patents from 2009-2011
Recent Patents on Biomarkers Nicotinamide Adenine Dinucleotide Based Therapeutics
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Medicinal Chemistry Antimicrobial Peptides: Mediators of Innate Immunity as Templates for the Development of Novel Anti-Infective and Immune Therapeutics
Current Pharmaceutical Design Principles and Practices of Pathway Modelling
Current Bioinformatics Synthesis and Cytotoxic Evaluation of Disubstituted N-Acylhydrazones Pyrazinecarbohydrazide Derivatives
Letters in Drug Design & Discovery Biospecies Capture and Detection at Low Concentration
Micro and Nanosystems Current Update on Eosinophilic Lung Diseases and Anti-IL-5 Treatment
Recent Patents on Anti-Infective Drug Discovery